Ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension by 55%, according to recent study results.

JERUSALEM (AP) — Netanyahu says Israel has “many more surprises” for the next phase of its Iran operation.

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial, setting the company up to seek FDA approval in pulmonary arterial ...

United Therapeutics plans to file for approval of ralinepag as a treatment for pulmonary arterial hypertension (PAH) before the end of the year, after positive results in a phase 3 trial. The drug ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best penny stocks under $1 to buy right now. On February 23, Gossamer Bio announced topline results from its Phase 3 PROSERA study evaluating seralutinib ...

Thank you for standing by. My name is Dina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Bio Inc. PROSERA Phase 3 Topline Results Call. ...

- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...

The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...